An observational study in Covid19, Hematologic Malignancy and Vaccine Response Impaired, sponsored by Centre Hospitalier de Cornouaille. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-30.
Sponsored by Centre Hospitalier de Cornouaille · Observational
Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in December 2019 in Wuhan, China. Infection with this new coronavirus called SARS-CoV-2 can lead to fatal pneumonia associated with high rates of hospitalization in intensive care units (ICU).
Hospitalized patients with hematologic malignancies have a higher mortality rate than patients without hematologic malignancies (62% vs. 8%). The severity of Covid-19 may be related to their treatment, in particular anti-CD20 used in B lymphoid hemopathies. In fact, anti-CD20 antibodies induce rapid and prolonged depletion of B cells, but they are necessary for development. humoral immune responses.
But currently, no immunogenicity data are known for patients with hemopathy or in those on anti-lymphocyte immunochemotherapy.
The aim of this study is to evaluate the humoral response after vaccination against SARS-CoV-2 in a French multicenter cohort of patients with hemopathies. Analysis of hemopathies and immunochemotherapy subgroups will determine whether there is a need to strengthen immunization schedules. In addition, the study wish to assess the safety and clinical efficacy of mRNA vaccines in this cohort.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 1,000 is above the median of 261 across 3,136 observational studies indexed under COVID-19.
Browse COVID-19 studies →Centre Hospitalier de Cornouaille is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with hemopathy followed in declared hospitals
Exclusion Criteria:
optimal humoral response at 1 month after COVID-19 vaccination
humoral response after COVID19 vaccination
SARS-CoV-2 Trimeric S IgG titers (BAU/ml)
Time frame: 1 month after vaccination
humoral response after COVID19 vaccination
SARS-CoV-2 Trimeric S IgG titers (BAU/ml)
Time frame: before first dose vaccination
humoral response after COVID19 vaccination
SARS-CoV-2 Trimeric S IgG titers (BAU/ml)
Time frame: before second dose vaccination
humoral response after COVID19 vaccination
SARS-CoV-2 Trimeric S IgG titers (BAU/ml)
Time frame: 3 months after vaccination
humoral response after COVID19 vaccination
SARS-CoV-2 Trimeric S IgG titers (BAU/ml)
Time frame: 6 months after vaccination
humoral response after COVID19 vaccination
SARS-CoV-2 Trimeric S IgG titers (BAU/ml)
Time frame: 12 months after vaccination
clinical response after COVID19 vaccination
SARS-CoV-2 disease onset in the follow-up
Time frame: 12 months after vaccination
security of mRNA COVID19 vaccine
side effects onset in the follow-up
Time frame: 3 months after vaccination
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier de Cornouaille